Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study

Takashi Shibutani,Shoji Nagao,Kazuhiro Suzuki,Michiko Kaneda,Kasumi Yamamoto,Tomoatsu Jimi,Hiroko Yano,Miho Kitai,Takaya Shiozaki,Kazuko Matsuoka,Tamotsu Sudo,Satoshi Yamaguchi

Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study

2019

Takashi Shibutani
Shoji Nagao
Kazuhiro Suzuki
Michiko Kaneda
Kasumi Yamamoto
Tomoatsu Jimi
Hiroko Yano
Miho Kitai
Takaya Shiozaki
Kazuko Matsuoka
Tamotsu Sudo
Satoshi Yamaguchi

Background The purpose of this study was to determine the optimal regimen of neoadjuvant chemotherapy (NAC) for advanced epithelial ovarian, fallopian tube, and peritoneal cancers.

Keywords:

Oncology
Paclitaxel
Retrospective cohort study
Ovarian cancer
Carboplatin
Fallopian tube
Internal medicine
Pathology
Medicine
Regimen
Peritoneal cancer
Chemotherapy
Cancer
Gastroenterology
Hazard ratio
Debulking

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations